WHO世界卫生组织：世界卫生组织药品通讯（2024年第4期）（英文版）

Europe. The PRAC of the EMA has recommended updating the product information for cefotaxime and ethambutol, respectively, to include the risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and to strengthen advice on severe cutaneous adverse reactions (SCARs) including DRESS. Cefotaxime is an injectable third-generation cephalosporin antibiotic used to treat a variety of bacterial infections. Ethambutol is an antibiotic primarily used to treat tuberculosis. The updated product